Ocugen Inc (OCGN) - News Archive

Ocugen, Inc., a pioneering US-based biotechnology corporation listed on NASDAQ as OCGN, announced recently that it has successfully completed the dosing phase for the second cohort of its Phase 1/2 ArMaDa clinical trial...

In an exciting development for biotechnology company Ocugen, Inc., the European Medicines Agency s Committee for Medicinal Products for Human Use (CHMP) has offered positive scientific advice regarding the approval path...

Ocugen, Inc. Receives FDA Clearance for Phase 3 Clinical Trial of OCU400, the First Gene Therapy for Retinitis PigmentosaGene therapy is an exciting field in biotechnology that holds immense potential for treating a wid...

In a recent press release, Ocugen Inc. (NASDAQ: OCGN), a leading biotechnology firm specializing in gene and cell therapies and vaccines, shared positive news regarding their Phase 1/2 ArMaDa clinical trial for OCU410a...

MALVERN, Pa., April 01, 2024 - Ocugen, Inc. (NASDAQ: OCGN), a leading biotechnology company focused on gene and cell therapies and vaccines, shared exciting updates regarding their ongoing clinical trials for Stargardt...

In a strategic move to strengthen its position in the biotechnology industry, Ocugen Inc. (NASDAQ: OCGN) has recently appointed Dr. Huma Qamar as its new Chief Medical Officer (CMO). The addition of Dr. Qamar to the Ocu...

Dosing Completion of Phase 1/2 Clinical Trial for OCU410 Gene Therapy Candidate in Geographic Atrophy Signals Progress for OcugenOcugen, Inc. (NASDAQ: OCGN), a biotechnology company specialized in gene and cell therapie...

Ocugen, Inc. (NASDAQ: OCGN), a leading biotechnology company dedicated to the development and commercialization of innovative gene and cell therapies and vaccines, recently announced the availability of its Clinical Sho...

Ocugen, Inc., a biotechnology company dedicated to the development of gene and cell therapies and vaccines, recently announced the completion of dosing in the first cohort of its Phase 1/2 clinical trial for OCU410ST, a...

In what is a landmark development, Ocugen, Inc., a trailblazer in the biotechnology industry specializing in novel gene and cell therapies, has announced its entry on the stage of the Pharma Market Research Conference (...

Ocugen, Inc., an influential player in the ever-evolving biotechnology industry, has taken an assertive step towards revolutionizing the systemic approach to tackling dry age-related macular degeneration (dAMD). The Pen...